Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Foxwoods Man, drkazmd65
Search This Board:
Last Post: 10/21/2014 1:28:02 PM - Followers: 161 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering 10/21/2014 09:42:00 AM
CVM News: CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants 10/21/2014 09:15:00 AM
CVM News: CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants 10/20/2014 04:30:00 PM
CVM News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 10/20/2014 04:27:28 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/14/2014 09:49:50 AM
News News Alert: CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering 10/21/2014 09:42:00 AM
PostSubject
#6215  Sticky Note http://www.marketwatch.com/story/small-companies-lead-the-i-o-class-of-cancer-th majatamata 08/08/14 11:00:50 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#6342   I got filled @ .17. I won't worry Turney 10/21/14 01:28:02 PM
#6341   In lieu of a marketable product at this tprosuper 10/21/14 11:04:54 AM
#6340   I added....price % drop was enough to average learning curve 10/21/14 11:00:22 AM
#6339   This company is a pos ... They do Spike5 10/21/14 09:52:17 AM
#6338   Put in an order for 5000 more warrants Turney 10/21/14 09:47:47 AM
#6337   I've got 24 followers....does any of you contribute learning curve 10/20/14 09:30:50 PM
#6336   why put a cap/ overhang of 4 years learning curve 10/20/14 08:26:59 PM
#6335   After Hours - Timberrrrr! kpisme 10/20/14 08:07:57 PM
#6334   What is next? learning curve 10/20/14 06:39:13 PM
#6333   Correct...but I DO know that this ain't gonna happen: Foxwoods Man 10/17/14 04:49:12 PM
#6332   You don't know that for sure, what about Turney 10/17/14 04:37:44 PM
#6331   Non-issue with CVM.... Foxwoods Man 10/17/14 04:05:16 PM
#6330   We are under the spell of EBOLA I Turney 10/17/14 09:14:12 AM
#6329   Here is a 10-15 day story..... learning curve 10/16/14 10:31:31 PM
#6328   Never a bad sign when that happens. drkazmd65 10/14/14 02:58:40 PM
#6327   Good pickup..I just assumed they were a perk...nope...open Foxwoods Man 10/14/14 11:50:54 AM
#6326   Purchased on the open market... Thats a good sign.. majatamata 10/14/14 11:45:07 AM
#6325   outa here again. betting on after bell Friday learning curve 10/10/14 03:21:35 PM
#6324   So, even you admit CVM has at least Foxwoods Man 10/09/14 01:04:52 PM
#6323   If DeClara can get rid of us shareholders Turney 10/09/14 11:26:39 AM
#6322   CVM tanking again!!! I run. Why cant this Thinking-Longterm 10/09/14 10:01:04 AM
#6321   As you know that is a $1 million Foxwoods Man 10/09/14 07:05:15 AM
#6320   It may not be Gert but DeClara the Turney 10/09/14 01:12:48 AM
#6319   I'm not against shorts opinion---all have value... learning curve 10/08/14 09:56:38 PM
#6318   They need cash. Yes that would help. Mm learning curve 10/08/14 09:47:01 PM
#6317   Gert is not a "lien holder"..he is the Foxwoods Man 10/08/14 05:24:00 PM
#6316   Gert sure is a LIENHOLDER and I bet Turney 10/08/14 05:10:56 PM
#6315   Maybe I missed something but who are the Foxwoods Man 10/08/14 03:45:37 PM
#6314   I hope our lienholders, bondholders and anyone else Turney 10/08/14 02:42:07 PM
#6313   Decent logic... but.... if the arbitrator wakes up Foxwoods Man 10/08/14 06:42:09 AM
#6312   It wouldn't be a reason for me to learning curve 10/07/14 09:00:05 PM
#6311   Thanks. I only recalled TEVA had some relationship learning curve 10/07/14 08:42:20 PM
#6310   Yep,..... and as long as the posters involved drkazmd65 10/07/14 05:26:00 PM
#6309   Ok, this is typical example of forum logic: Foxwoods Man 10/07/14 03:16:16 PM
#6308   No, I don't know if they even own Turney 10/07/14 01:13:44 PM
#6307   same here....only a few for me... learning curve 10/07/14 10:25:05 AM
#6306   Bought some 82's.... Foxwoods Man 10/07/14 10:23:32 AM
#6305   I bought a small bit based on ID learning curve 10/07/14 10:10:01 AM
#6304   Pretty low volume for a "liquidation".... Foxwoods Man 10/06/14 05:03:51 PM
#6303   I wouldn't think TEVA is any happier with Astavakra 10/06/14 04:06:04 PM
#6302   Maybe that's who is liquidating? learning curve 10/06/14 03:51:42 PM
#6301   Teva refocusing research; I hope CVM is not Turney 10/06/14 01:25:40 PM
#6300   Unknown to me, Sorry....EOM goodplenty100 10/04/14 01:51:46 PM
#6299   Do they get any early look ins? Is majatamata 10/04/14 07:46:28 AM
#6298   Well - at least enrollment is steady and drkazmd65 10/03/14 04:12:41 PM
#6297   Patient enrollment still shy of projections in Multikine kurious 10/03/14 10:51:13 AM
#6296   Well our total enrollees for the month of tprosuper 10/03/14 10:39:09 AM
#6295   http://www.nytimes.com/2009/08/03/health/research/03trials.html?pagewanted=all&_ kurious 10/03/14 10:30:47 AM
#6294   enrollment slow and not expected to reach total kurious 10/03/14 10:16:04 AM
#6293   BioMed reports goodplenty100 10/03/14 09:27:48 AM
PostSubject